Our study aims at finding microbial etiology, antibiotic susceptibility and clinical outcomes of HCAP.
METHODS: ATS/IDSA criteria were used for including patients in two groups -HCAP and HAP. Total 318 patients meeting criteria (Excluding CAP), were grouped in HCAP -165 cases (52%) and HAP (including VAP) -153 controls (48%). Microbiological investigations: Sputum and Endo -tracheal aspirate (ETA) cultures were done using Blood agar, MacConkey agar and Chocolate agar. BacT/ALERTÒ 3D automated system was used for blood cultures. Antibiotic susceptibility testing of isolates from sputum and ETA was done by Kirby and Bauer Disc Diffusion method as per Clinical Laboratory Standard Institute (CLSI) guidelines. Antibiotic susceptibility testing of isolates from blood was done on VITEK 2. CONCLUSIONS: HCAP needs to be categorised separately as the third category, if not in HAP spectrum, because the patient characteristics, bacterial agents, antibiotic susceptibility and mortality although similar and comparable to HAP, are unique to HCAP, and can be better addressed when categorised separately. The increase in mortality in HCAP is multifactorial, clinical (increasing age, comorbidities, pneumonia severity and complications) and microbiological (the type of bacteria and antibiotic susceptibility) and use of empirical antibiotic therapy is justified which can be modified later as per culture results and local microbial ecology.
RESULTS: Culture results Escherichia coli (E. coli) was the commonest agent in HCAP [n¼30 (18%)], followed by
CLINICAL IMPLICATIONS: Our study highlights the alarming incidence of antibiotic resistant bacteria in HCAP like HAP, most of which belong to ESCAPE group of bacteria. Targeting this group using empirical antibiotics can be helpful -in clinical and in research areas.
